Bristol Myers Squibb (BMY)

[DewDiligence]

Opdivo monotherapy shows statsig DFS benefit vs placebo in adjuvant esophageal or GEJ cancer in phase-3 CHECKMATE-577 study:

https://www.businesswire.com/news/home/20200811005248/en

CheckMate-577 is a Phase 3 randomized, multi-center, double-blind study evaluating Opdivo as an adjuvant therapy in patients with resected esophageal or GEJ cancer who have received neoadjuvant CRT therapy and have not achieved a pathological complete response. The primary endpoint of the trial is DFS and the secondary endpoint is OS. Following neoadjuvant CRT therapy and complete tumor surgical resection, patients were randomized to receive placebo or Opdivo 240 mg by intravenous infusion every two weeks for 16 weeks followed by Opdivo 480 mg every four weeks until disease progression or unacceptable toxicity.